Thrivent Financial for Lutherans Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Thrivent Financial for Lutherans grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1,272.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 125,194 shares of the biopharmaceutical company's stock after purchasing an additional 116,074 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.11% of Regeneron Pharmaceuticals worth $89,179,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $26,000. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. Avalon Trust Co acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $36,000. Finally, Private Wealth Management Group LLC increased its holdings in Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 39 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

REGN traded down $4.14 during trading on Friday, hitting $658.48. 1,869,108 shares of the company traded hands, compared to its average volume of 634,475. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a market cap of $71.99 billion, a PE ratio of 17.20, a P/E/G ratio of 2.34 and a beta of 0.27. The stock's 50-day simple moving average is $689.43 and its two-hundred day simple moving average is $815.71. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $11.86 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.53%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective for the company. Bank of America reissued an "underperform" rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. TD Cowen decreased their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research note on Tuesday, February 4th. Finally, BMO Capital Markets decreased their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.